Palisade Bio, Inc. Common Stock
Here’s whether Palisade Bio, Inc. Common Stock (PALI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); RSI 45 — healthy momentum range; strong 1-year return of +75.7%. Concerns: 50-day MA is falling (-0.27% over 10 days); 3-month momentum negative (-6.2%); declining volume on rally — weak conviction (0.69x 30d avg). Currently 31.7% off its 52-week high. Score: +2/7.
PALI is in a confirmed uptrend, trading above both its 50-day ($1.91) and 200-day ($1.92) moving averages. An RSI of 44.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +75.7% compares to +16.5% for SPY (beat the market by 59.2%). The current 31.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.